Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 4Terminated 2Recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 14Tumor-Agnostic 4Genitourinary 4Breast 3Sarcoma 2Gastrointestinal 2CNS 2Thoracic 1Other solid neoplasm 1Head & Neck 1

Conditions

Brain Neoplasms 2Glioblastoma 1

Interventions

Temozolomide 79Magnetic Resonance Spectroscopy 68Specimen Handling 45Radiotherapy 42Bevacizumab 29Radiosurgery 27Cyclophosphamide 27Radiation 20pembrolizumab 19Blood Specimen Collection 19fludarabine 16Nivolumab 16Irinotecan 15Carboplatin 13Biopsy 13Etoposide 12Vincristine 11Pemetrexed 11Lomustine 11dinutuximab 9Surgical Procedures, Operative 9trametinib 8abemaciclib 8Ipilimumab 8naxitamab 7fluciclovine F-18 7Watchful Waiting 7Topotecan 7Proton Therapy 7Magnetic Resonance Imaging 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × niraparib × CNS × Clear all
NCT06388733 2026-04-01

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NeuroTrials, LLC

Phase 3 Recruiting
450 enrolled
CNS

Brain Neoplasms, Glioblastoma

NCT05700721 2026-02-05

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

M.D. Anderson Cancer Center

Phase 2 Recruiting
120 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡